Entasis Therapeutics Holdings Inc (ETTX) Stock News

USA - NASDAQ:ETTX - US2936141033 - Common Stock

2.19

-0.01 (-0.45%)

Last: 7/8/2022, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ETTX Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

3 years ago - By: Benzinga - Mentions: CAMP SEAC CXDO

Over $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are Buying

3 years ago - By: Innoviva, Inc. - Mentions: INVA

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

3 years ago - By: Rowley Law PLLC - Mentions: INVA

News Image

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.

3 years ago - By: Benzinga - Mentions: AZN INVA

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

3 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

3 years ago - By: Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX

3 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its transaction with Innoviva

3 years ago - By: Weiss Law - Mentions: INVA

SHAREHOLDER ALERT: Weiss Law Investigates Entasis Therapeutics Holdings Inc.

3 years ago - By: Kahn Swick & Foti, LLC

ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX

3 years ago - By: Halper Sadeh LLP

ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to Shareholders

3 years ago - By: Innoviva, Inc. - Mentions: INVA

Innoviva to Acquire Entasis Therapeutics

3 years ago - By: Entasis Therapeutics Holdings Inc.

Innoviva to Acquire Entasis Therapeutics

4 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update

4 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

4 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

4 years ago - By: InvestorPlace - Mentions: HST ACAD SBUX MU ...

Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today

4 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update

4 years ago - By: Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.